EsoBiotec ready to transform cell therapy cancer treatments pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
LIEGE, Belgium, June 3, 2021 /PRNewswire/ Amyl Therapeutics ( Amyl ), a preclinical stage biotechnology company developing its amyloid fibrils specific
technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18.3 million Series A financing. The funding round comprises €8.6 million in equity led by Noshaq - a regional Belgian private-public fund - with support from Merieux Participations, Sambrinvest and other private investors; and €9.7 million in non-dilutive funding from the DG06 – a key policy-design and implementing body for research and innovation policy in the Walloon region of Belgium.